Six Directors at Commerzbank AG bought 8,563 shares at between 24.600EUR and 24.903EUR. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
NEWS SUMMARY: CAF, CELLNEX, INMOBILIARIA COLONIAL, MELIÁ. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 1Q’25 results to be released over the coming days in Spain. Euro STOXX 50 nearing April highs European stock markets rose following the Fed meeting and progress made in tariff matters. In the STOXX 600, the best-performing sectors were Industrials and Technology, whereas d...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAF, CELLNEX, INMOBILIARIA COLONIAL, MELIÁ. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’25 que se publicarán en España y Europa en los próximos días. El Euro STOXX 50 se acerca a los máximos de abril Avances en Europa tras la reunión de la Fed y los progresos en materia comercial. En el STOXX 600 lo...
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 270.2 million, +10.7%, margin on revenue of 39.7% Adjusted net income(2) of € 175.5 million, +7.2% Net income of € 125.0 million, +1.2% Free cash flow(4) of € 158.8 million, +€ 11.7 million vs prior yearNet debt(5) at € 2,020.8 million, just below 2.2x EBITDA pro-forma(6)Ist...
Branicks Q1 25 results: Further increase in vacancy; fundamentally not improving|Teva: Q1 2025 results up slightly. Strong momentum in innovative medicines and the new efficiency programme lend credibility to the 2027 guidance.|TPG steps away from Techem acquisition; documentation subject to special call|Banco BPM reports solid Q1 performance|
Branicks Q1 25 results: Further increase in vacancy; fundamentally not improving|Teva : résultats au T1 2025 en légère hausse. La bonne dynamique des médicaments innovants et le nouveau programme d’efficience crédibilisent la guidance 2027.|TPG steps away from Techem acquisition; documentation subject to special call|BPM publie un trimestre record et au-dessus des attentes|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.